AbbVie Inc., US00287Y1091

AbbVie stock: Piper Sandler raises price target to USD 349

Published on 11/18/2026 at 16:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Piper Sandler lifted its AbbVie stock target after the third-quarter update and kept an Overweight rating. The call highlights pipeline durability.

Fresh analyst view on AbbVie

  • Piper Sandler cited long-term growth potential in AbbVie's immunology portfolio and maintained its Overweight rating.
  • The view highlights Skyrizi combination products, zumilokibart and franchise durability beyond upcoming exclusivity risks.
  • AbbVie stock traded at 264.50 euros on Lang & Schwarz on Wednesday afternoon.
AbbVie Inc., US00287Y1091, Illustration mit AI erstellt.

AbbVie stock: Piper Sandler raises price target to USD 349

Piper Sandler raised its price target for AbbVie from USD 303 to USD 349 on Tuesday, November 17, while maintaining an Overweight rating, according to Investing.com. The analyst action followed AbbVie's third-quarter update and adds a new sell-side view after several firms raised their assessments.

Pipeline supports the revised view

Piper Sandler pointed to AbbVie's top-line and EBITDA growth profile through the end of the decade. The firm also cited greater visibility for Skyrizi-containing combination products in inflammatory bowel disease and the longer-term franchise potential of the immunology portfolio.

The note highlighted the development of zumilokibart in atopic dermatitis and other indications. Piper Sandler linked those programs to the broader durability of AbbVie's immunology business as investors look beyond eventual exclusivity losses for Skyrizi and Rinvoq.

Third-quarter backdrop remains central

AbbVie reported third-quarter revenue of USD 17.4 billion, with Skyrizi and Rinvoq among the main growth drivers. Management also raised its 2026 adjusted earnings outlook, providing the operating backdrop for the recent cluster of analyst actions.

For investors, the revised target raises the bar for pipeline execution and commercial follow-through. The valuation case depends on whether newer immunology products can extend growth while established medicines face pricing and patent-related pressure.

AbbVie stock traded at 264.50 euros on Lang & Schwarz at 16:02 CET on Wednesday, November 18, 2026.

AbbVie Inc. stock facts

  • Company: AbbVie Inc.
  • ISIN: US00287Y1091
  • Ticker: ABBV
  • Home exchange: NYSE
  • Trading venue: Lang & Schwarz
  • Quote: 264.50 euros at 16:02 CET on November 18, 2026

Broader market developments can shape healthcare valuations; see Current market reports.

More news and analyses on AbbVie stock.

Disclaimer...
en | US00287Y1091 | ABBVIE INC. | boerse | 70531433 | bgmi